CNS Pharmaceuticals, Inc.
CNSP
$5.52
-$0.60-9.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -87.50% | 42.59% | 6.16% | -21.34% | 40.91% |
| Total Depreciation and Amortization | 0.00% | -12.50% | 37.50% | 37.50% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.56% | -97.87% | -90.70% | -69.22% | -44.10% |
| Change in Net Operating Assets | 216.08% | 149.70% | -563.54% | 567.94% | -193.09% |
| Cash from Operations | 44.22% | 68.03% | -223.76% | -1.56% | -115.70% |
| Capital Expenditure | -333.33% | -- | -- | -- | -90.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -333.33% | -- | -- | -- | -90.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 1.28% | 1.19% | 1.11% | 0.91% | 55.87% |
| Issuance of Common Stock | -89.98% | -99.99% | 85.53% | 154.72% | 104.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -541.00% | 96.25% | 100.00% | -- | 95.07% |
| Cash from Financing | -91.80% | -100.75% | 90.21% | 184.16% | 127.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -420.44% | -141.33% | -235.69% | 2,371.37% | -41.82% |